Aktuelle Dermatologie 2024; 50(07): 308-313
DOI: 10.1055/a-2261-9018

Alopecia areata – ein Update

Alopecia areata – an update
Stephanie Marie Huber
1   Dermatologische Klinik, Universitätsspital Basel, Basel, Schweiz
Alexander A. Navarini
1   Dermatologische Klinik, Universitätsspital Basel, Basel, Schweiz
Ralph P. Braun
2   Dermatologische Klinik, UniversitätsSpital Zürich, Zürich, Schweiz
Christian Greis
2   Dermatologische Klinik, UniversitätsSpital Zürich, Zürich, Schweiz
› Author Affiliations


Alopecia areata (AA) – der kreisrunde Haarausfall – stellt nach der androgenetischen Alopezie die zweithäufigste Haarverlusterkrankung weltweit dar. Es wird vermutet, dass es infolge des Verlusts des Immunprivilegs des Haarfollikels zu einer Destruktion der Zellen des Haarfollikels kommt. Der konsekutive Haarausfall geht mit erheblichen Auswirkungen auf die Lebensqualität einher. Die Spontanremission liegt insbesondere bei leichteren Verlaufsformen bei bis zu 80%. Es bestehen topische, injizierbare und systemische immunsupprimierende bzw. -modulierende Behandlungsmöglichkeiten. Vielversprechend scheinen v.a. systemisch verabreichte JAK-Inhibitoren zu sein.


Alopecia areata (AA) – circular hair loss – is the second most common hair loss disease worldwide after androgenetic alopecia. It is assumed that the loss of the immune privilege of the hair follicle leads to the destruction of the cells of the hair follicle. The consecutive hair loss is associated with considerable effects on quality of life. The spontaneous remission rate, especially in milder forms, can be up to 80%. There are topical, injectable, and systemic immunosuppressive or immunomodulating treatment options available. Systemically administered JAK inhibitors appear to be particularly promising.

Publication History

Article published online:
13 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Literatur

  • 1 Yousaf A, Lee J, Fang W. et al. Association Between Alopecia Areata and Natural Hair Color Among White Individuals. JAMA Dermatol 2021; e210144
  • 2 Tu TY, Chang R, Lai JN. et al. Human papillomavirus symptomatic infection associated with increased risk of new-onset alopecia areata: A nationwide population-based cohort study. J Autoimmun 2021; 119: 102618
  • 3 Dai YX, Yeh FY, Shen YJ. et al. Cigarette Smoking, Alcohol Consumption, and Risk of Alopecia Areata: A Population-Based Cohort Study in Taiwan. Am J Clin Dermatol 2020; 21: 901-911
  • 4 Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol 2018; 57: 776-783
  • 5 Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med 2022; 54: 694-712
  • 6 Ovcharenko Y, Serbina I, Zlotogorski A. et al. Renbök phenomenon in an alopecia areata patient with psoriasis. Int J Trichology 2013; 5: 194-195
  • 7 Olsen E, Hordinsky M, McDonald-Hull S. et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999; 40: 242-246
  • 8 Gudobba C, Mane T, Bayramova A. et al. Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores. JAMA Dermatol 2023; 159: 143-150
  • 9 Rudnicka L, Olszewska M, Rakowska A. Atlas of Trichoscopy. London: Springer; 2012
  • 10 Kempf W, Hantschke M, Kutzner H. et al. Dermatopathologie. Berlin: Springer; 2020
  • 11 Nomiyama T, Katoh N. Clobetasol propionate 0.05% under occlusion for alopecia areata: Clinical effect and influence on intraocular pressure. Australas J Dermatol 2021; 62: e262-e264
  • 12 Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52: 138-139
  • 13 Yee BE, Tong Y, Goldenberg A. et al. Efficacy of different concentrations of intral­esional triamcinolone acetonide for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol 2020; 82: 1018-1021
  • 14 Rastaghi F, Kaveh R, Yazdanpanah N. et al. The Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata: A Review Article. Dermatol Pract Concept 2023; 13: e2023255
  • 15 Fukumoto T, Fukumoto R, Magno E. et al. Treatments for alopecia areata: A systematic review and network meta-analysis. Dermatol Ther 2021; 34: e14916
  • 16 King B, Ohyama M, Kwon O. et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med 2022; 386: 1687-1699
  • 17 King B, Guttman-Yassky E, Peeva E. et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol 2021; 85: 379-387
  • 18 Peeva E, Guttman-Yassky E, Banerjee A. et al. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol 2022; 87: 390-393
  • 19 Dai Z, Chen J, Chang Y. et al. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight 2021; 6: 142205
  • 20 Dhurat R, Sharma R. A Practical Approach to the Treatment of Alopecia Areata. Indian Dermatol Online J 2022; 13: 725-728
  • 21 Roohaninasab M, Goodarzi A, Ghassemi M. et al. Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. Dermatol Ther 2021; 34: e14768
  • 22 Cruciani M, Masiello F, Pati I. et al. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfus 2023; 21: 24-36